Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
CA 2360374 A1 · Owner: Beth Israel Deaconess Medical Center · Inventors: Lawler, John W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Tumors attract blood vessels in order to grow by a process called angiogenesis. The relative quantity of stimulators and inhibitors is an important determining factor for the initiation of angiogenesis. Thrombospondins-1 and -2 are adhesive glycoproteine that have the ability to inhibit aniogenesis. This inhibiting activity has been mapped to the type 1 repeats of TSP-1 and TSP-2. The invention includes chimeric proteins that contain anti-angiogenic portions of TSP-1 TSP-2, endostatin, angiostatin, platelet factor 4 or prolactin, linked to a portion of the N-terminal region of human cartilage oligomeric matrix protein (COMP) that allows formation of pentamers. Also described herein …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 1, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 1, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 1, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.